NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Heidelberg Pharma's HDP-101 Clinical Data Presentation and R&D Webinar
TL;DR
Heidelberg Pharma's HDP-101 shows promising anti-tumor activity, offering a potential competitive advantage in treating relapsed multiple myeloma with novel Amanitin-based ADC technology.
HDP-101 is an anti-BCMA antibody-drug conjugate undergoing Phase I/IIa clinical trials to determine optimal dosing and safety for relapsed or refractory multiple myeloma treatment.
This innovative cancer therapy addresses high unmet medical needs in multiple myeloma patients, potentially improving survival and quality of life for those with limited treatment options.
Heidelberg Pharma pioneers using Amanitin from death cap mushrooms in cancer therapy, presenting breakthrough data at the World ADC Congress and hosting a November 11 webinar.
Found this article helpful?
Share it with your network and spread the knowledge!
HDP-101 (INN: pamlectabart tismanitin) is an anti-BCMA antibody-drug conjugate being investigated for the treatment of relapsed or refractory multiple myeloma, a bone marrow cancer with high unmet medical need.
Professor Andreas Pahl will present an update from patient cohort 8 including efficacy data from the ongoing Phase I/IIa study, showing objective responses and promising anti-tumor activity observed in several patients across multiple cohorts.
The presentation is scheduled for Wednesday, 5 November 2025, at 5:00 pm PST at the Town & Country San Diego location during the 16th Annual World ADC Congress from 3 to 6 November 2025.
The R&D webinar on 11 November 2025 at 05:00 pm CET (08:00 am PST) is for investors, analysts, and media to provide detailed insights about the clinical data and features presentations by Heidelberg Pharma management and Key Opinion Leader Professor Marc-Steffen Raab.
The data reinforces the therapeutic potential and safety profile of HDP-101 in relapsed or refractory multiple myeloma, showing promising anti-tumor activity in patients with this difficult-to-treat cancer.
Participants can register using the provided link: https://us06web.zoom.us/webinar/register/WN_AG_mESPaT-aSsm8_O2DllA and will have the opportunity to submit questions in advance or ask questions live during the event.
HDP-101 is currently in an ongoing Phase I/IIa clinical trial, with Phase I being a dose-escalation trial designed to determine the optimal and safe dose level for subsequent Phase II clinical evaluation.
Professor Andreas Pahl, Chief Executive Officer of Heidelberg Pharma, will present at the World ADC Congress, while the R&D webinar will feature both Heidelberg Pharma management and Key Opinion Leader Professor Marc-Steffen Raab, Head of the Myeloma Center at University Hospital Heidelberg.
Yes, a recording of the R&D webinar will be accessible via the press & investor section of the Company website after the event.
Curated from NewMediaWire
